98140452 - VOYAGER THERAPEUTICS

Information

• Trademark
• 98140452

• Source

• Serial Number

  98140452

• International Classifications

  • 5 - Pharmaceutical and veterinary preparations
  • 42 - Scientific and technological services and research and design relating thereto
  • 44 - Medical services
  • 45 - Legal services

• Filing Date

  August 18, 2023
  a year ago

• Transaction Date

  September 27, 2024
  4 months ago

• Status Date

  September 23, 2024
  4 months ago

• Location Date

  September 23, 2024
  4 months ago

• Status Code

  653

• Current Location

  TMEG LAW OFFICE 103

  Employee Name

  CHISOLM, KEVON

• Attorney Docket Number

  135333-91001

  Attorney Name

  Keith Toms, Esq.

  Law Office Assigned Location Code

  L30

• Owners

  • Voyager Therapeutics

Case File Statements

• DM0000: The mark consists of the word "VOYAGER" above the word "THERAPEUTICS" with a half circle between the "VOY" and "AGER" portions of the mark.
• GS0051: Biological preparations for gene therapy; adeno-associated virus (AAV) gene therapy preparations and pharmaceuticals; Biological preparations for treatment of neurological diseases and disorders; antibody and gene therapy preparations for treatment of disease, namely, neurological diseases; medical preparations and pharmaceuticals for treatment of neurological diseases via antibody, gene replacement, gene knockdown, or vectorized antibodies; antibody and gene therapy preparations for neurological diseases; nucleic acids encoding polypeptides for gene therapy; Drug delivery agents comprising compounds that facilitate delivery of a wide range of pharmaceuticals and biotherapeutics; Drug delivery agents comprising capsids viral platforms, and non-viral platforms, that facilitate delivery of a wide range of pharmaceuticals and biotherapeutics; pharmaceutical for the treatment of neurodegenerative diseases and diseases of the central nervous system, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, Friedreich's Ataxia, Huntington's disease, and prion disease
• CC0000: Color is not claimed as a feature of the mark.
• GS0451: Collaboration services in the field of platform technologies for delivery of therapies and pharmaceuticals, namely, licensing of intellectual property
• GS0441: Medical services provided for clinical trials; providing patient care for clinical trials; providing medical information in the field of gene therapy; providing a website featuring medical information; medical treatment of neurological diseases, neurodegenerative diseases, and diseases of the central nervous system, including Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, Friedreich's Ataxia, and Huntington's disease, and prion disease
• DS0000: "THERAPEUTICS"
• GS0421: Biotechnology research services; research and development of platform technologies for delivery of therapies; research and development of platform technologies for delivery of gene therapies, antibody therapies and pharmaceuticals; research and development regarding the use of RNA-based functional screening platforms to discover, research and develop novel capsids for genetic delivery of therapies and pharmaceuticals; Pharmaceutical research and development in the field of gene therapy and antibody therapy; Pharmaceutical research and development for the treatment of neurological diseases and disorders; scientific research in the field of gene therapy and antibody therapy; pharmaceutical research services; research and development of pharmaceutical preparations for non-viral and gene therapy; research and development of pharmaceutical preparations for neurological diseases; biotechnology research services; research and development in the pharmaceutical and biotechnology fields; research and development regarding the delivery of therapies across the blood-brain barrier; research and development regarding the non-viral and viral vectors for the delivery of therapeutic agents; research and development regarding the identification and targeting of specific cells and tissues for gene therapy; providing scientific research information in the field of clinical trials; hosting a website featuring medical research information

Case File Event Statements

• 9/19/2023 - a year ago

  3 - NOTICE OF DESIGN SEARCH CODE E-MAILED Type: MDSC

• 8/22/2023 - a year ago

  1 - NEW APPLICATION ENTERED Type: NWAP

• 9/18/2023 - a year ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 4/23/2024 - 9 months ago

  5 - NON-FINAL ACTION WRITTEN Type: CNRT

• 4/17/2024 - 9 months ago

  4 - ASSIGNED TO EXAMINER Type: DOCK

• 4/23/2024 - 9 months ago

  6 - NON-FINAL ACTION E-MAILED Type: GNRT

• 4/23/2024 - 9 months ago

  7 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 7/22/2024 - 6 months ago

  10 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA

• 7/22/2024 - 6 months ago

  9 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN

• 7/22/2024 - 6 months ago

  8 - TEAS CHANGE OF OWNER ADDRESS RECEIVED Type: COAR

• 7/23/2024 - 6 months ago

  11 - APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Type: XELR

• 7/23/2024 - 6 months ago

  12 - APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Type: XELG

• 9/19/2024 - 4 months ago

  13 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA

• 9/19/2024 - 4 months ago

  14 - EXAMINERS AMENDMENT E-MAILED Type: GNEA

• 9/19/2024 - 4 months ago

  15 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN

• 9/20/2024 - 4 months ago

  16 - ASSIGNED TO LIE Type: ALIE

• 9/23/2024 - 4 months ago

  19 - LETTER OF SUSPENSION E-MAILED Type: GNSL

• 9/20/2024 - 4 months ago

  17 - EXAMINER'S AMENDMENT ENTERED Type: XAEC

• 9/23/2024 - 4 months ago

  18 - SUSPENSION LETTER WRITTEN Type: CNSL

• 9/23/2024 - 4 months ago

  20 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3